Last reviewed · How we verify
NCT06593964
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
NA trial testing Thermosensitive Nanogel Embolic Agent in Unresectable Hepatocellular Carcinoma in 188 participants. Currently enrolling.
30 April 2026
Quick facts
| Lead sponsor | Zhongda Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 188 |
| Start date | 10 September 2024 |
| Primary completion | 30 April 2026 |
| Estimated completion | 30 April 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Thermosensitive Nanogel Embolic Agent
Conditions studied
- Unresectable Hepatocellular Carcinoma — all drugs for Unresectable Hepatocellular Carcinoma →
Sponsor
Zhongda Hospital
Who can join
Adults 18 to 80, any sex, with Unresectable Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06593964
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Unresectable Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
- NCT06911255 — Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT06909708 — SIRT Versus cTACE for Unresectable HCC (CHANCE2506) · NA · recruiting
- NCT07141056 — The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study · recruiting
Other Zhongda Hospital trials
Trials by the same sponsor.
- NCT07516704 — Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoa · EARLY_PHASE1 · not yet recruiting
- NCT07504731 — Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability · recruiting
- NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
- NCT07311915 — Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in Hi · NA · not yet recruiting
- NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06593964 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongda Hospital
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06593964.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing